Theragenics was established in 1981 and swiftly emerged as a global frontrunner in the production of radioactive brachytherapy seeds for the management of localized prostate cancer. In 2005, we initiated diversification of our operations through the acquisition of CP Medical, Inc., and have since continued to broaden our horizons with the procurement of Galt Medical Corp., NeedleTech Products, Inc., Concert Medical, and Arrotek.